Asks for

The ad says“Applicants must be board certified in Pathology (AP, CP, or AP/CP) and Molecular Genetic Pathology.”
The ad says“Applicants must be board certified in Pathology (AP, CP, or AP/CP) and Molecular Genetic Pathology.”
The ad says“Strong diagnostic expertise in building and signing out molecular diagnostics (including genomic and transcriptomic NGS, methylation testing, liquid biopsy testing, long read sequencing) is required. Expertise or interest in developing cutting-edge “post-genomic” precision diagnostics such as Artificial Intelligence Pathology, multiomic diagnostics, or cancer proteomics and metabolomics are desirable. Strong interest in further developing the crucial role of Pathology in clinical trials is a plus, including new companion diagnostics.”
The ad says“Strong diagnostic expertise in building and signing out molecular diagnostics (including genomic and transcriptomic NGS, methylation testing, liquid biopsy testing, long read sequencing) is required. Expertise or interest in developing cutting-edge “post-genomic” precision diagnostics such as Artificial Intelligence Pathology, multiomic diagnostics, or cancer proteomics and metabolomics are desirable. Strong interest in further developing the crucial role of Pathology in clinical trials is a plus, including new companion diagnostics.”
The ad says“Strong diagnostic expertise in building and signing out molecular diagnostics (including genomic and transcriptomic NGS, methylation testing, liquid biopsy testing, long read sequencing) is required. Expertise or interest in developing cutting-edge “post-genomic” precision diagnostics such as Artificial Intelligence Pathology, multiomic diagnostics, or cancer proteomics and metabolomics are desirable. Strong interest in further developing the crucial role of Pathology in clinical trials is a plus, including new companion diagnostics.”
The ad says“Strong diagnostic expertise in building and signing out molecular diagnostics (including genomic and transcriptomic NGS, methylation testing, liquid biopsy testing, long read sequencing) is required. Expertise or interest in developing cutting-edge “post-genomic” precision diagnostics such as Artificial Intelligence Pathology, multiomic diagnostics, or cancer proteomics and metabolomics are desirable. Strong interest in further developing the crucial role of Pathology in clinical trials is a plus, including new companion diagnostics.”
The ad says“Strong diagnostic expertise in building and signing out molecular diagnostics (including genomic and transcriptomic NGS, methylation testing, liquid biopsy testing, long read sequencing) is required. Expertise or interest in developing cutting-edge “post-genomic” precision diagnostics such as Artificial Intelligence Pathology, multiomic diagnostics, or cancer proteomics and metabolomics are desirable. Strong interest in further developing the crucial role of Pathology in clinical trials is a plus, including new companion diagnostics.”

Values

The ad says“Additionally, interest and expertise to sign out cases in an area of subspecialized Anatomic Pathology or Clinical Pathology is desirable.”
The ad says“Strong diagnostic expertise in building and signing out molecular diagnostics (including genomic and transcriptomic NGS, methylation testing, liquid biopsy testing, long read sequencing) is required. Expertise or interest in developing cutting-edge “post-genomic” precision diagnostics such as Artificial Intelligence Pathology, multiomic diagnostics, or cancer proteomics and metabolomics are desirable. Strong interest in further developing the crucial role of Pathology in clinical trials is a plus, including new companion diagnostics.”
The ad says“Strong diagnostic expertise in building and signing out molecular diagnostics (including genomic and transcriptomic NGS, methylation testing, liquid biopsy testing, long read sequencing) is required. Expertise or interest in developing cutting-edge “post-genomic” precision diagnostics such as Artificial Intelligence Pathology, multiomic diagnostics, or cancer proteomics and metabolomics are desirable. Strong interest in further developing the crucial role of Pathology in clinical trials is a plus, including new companion diagnostics.”
The ad says“Additionally, interest and expertise to sign out cases in an area of subspecialized Anatomic Pathology or Clinical Pathology is desirable.”
The ad says“Strong diagnostic expertise in building and signing out molecular diagnostics (including genomic and transcriptomic NGS, methylation testing, liquid biopsy testing, long read sequencing) is required. Expertise or interest in developing cutting-edge “post-genomic” precision diagnostics such as Artificial Intelligence Pathology, multiomic diagnostics, or cancer proteomics and metabolomics are desirable. Strong interest in further developing the crucial role of Pathology in clinical trials is a plus, including new companion diagnostics.”
The ad says“Strong diagnostic expertise in building and signing out molecular diagnostics (including genomic and transcriptomic NGS, methylation testing, liquid biopsy testing, long read sequencing) is required. Expertise or interest in developing cutting-edge “post-genomic” precision diagnostics such as Artificial Intelligence Pathology, multiomic diagnostics, or cancer proteomics and metabolomics are desirable. Strong interest in further developing the crucial role of Pathology in clinical trials is a plus, including new companion diagnostics.”

Job Description:

Molecular Pathologist (Open Rank)

Focus: With Additional Subspecialty Expertise in an Area of Anatomic Pathology or Clinical Pathology Desirable

(Academic Clinician or Physician-Scientist)

Department of Pathology

Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, Inc.

Harvard Medical School, Boston

The Department of Pathology at Beth Israel Deaconess Medical Center (BIDMC) is recruiting a full-time academic Molecular Pathologist (open rank, junior/mid-career/senior) with commensurate faculty appointment at Harvard Medical School. BIDMC is a tertiary care facility with 743 licensed beds and an internationally renowned principal teaching hospital of Harvard Medical School with NCI Comprehensive Cancer Center-affiliated Cancer Center.

The BIDMC Department of Pathology has launched new strategic initiatives in cutting-edge Precision Diagnostics (including cancer genomics, multiplex biomarker theranostics, and computational/digital pathology). As a teaching hospital of Harvard Medical School, BIDMC and the Department of Pathology, provide a clinically advanced and supportive academic environment for residents, fellows, and faculty. We’re also proud and excited to be an integral part of the landmark collaboration among Dana-Farber Cancer Institute (DFCI), Beth Israel Deaconess Medical Center (BIDMC), and Harvard Medical Faculty Physicians (HMFP) to establish New England’s only freestanding adult inpatient cancer hospital. The collaboration will provide unparalleled opportunities for pathology and other physician specialties to be part of DFCI’s internationally recognized cancer team.

We are looking for an active, energetic, team-oriented faculty member to help us shape our future agenda and engage in areas that are being actively developed.

Strong diagnostic expertise in building and signing out molecular diagnostics (including genomic and transcriptomic NGS, methylation testing, liquid biopsy testing, long read sequencing) is required. Expertise or interest in developing cutting-edge “post-genomic” precision diagnostics such as Artificial Intelligence Pathology, multiomic diagnostics, or cancer proteomics and metabolomics are desirable. Strong interest in further developing the crucial role of Pathology in clinical trials is a plus, including new companion diagnostics.

Additionally, interest and expertise to sign out cases in an area of subspecialized Anatomic Pathology or Clinical Pathology is desirable.

Candidates with a strong clinical, translational, or laboratory-based research program are particularly encouraged to apply. Candidates with existing NIH grant funding will be supported by attractive research space and start-up funds to expand their programs.

The successful candidate will join a team of faculty, residents, and fellows to provide world-class diagnostics at BIDMC. Additionally, the candidate will support the vibrant training programs, including pathology residency program, and multiple pathology fellowship programs.

Applicants must be board certified in Pathology (AP, CP, or AP/CP) and Molecular Genetic Pathology.

The candidate will be appointed to the full-time faculty of Harvard Medical School at an academic rank commensurate with experience.

For further questions or confidential position inquiries, please contact Dr. Gyorgy Abel, Director of Molecular Pathology and Genomics at BIDMC: gyorgy_abel@hms.harvard.edu

Research

Beth Israel Deaconess Medical Center consistently ranks as a national leader among independent hospitals in National Institutes of Health funding. Research funding totals over $229.8 million annually. BIDMC researchers run more than 850 active sponsored projects and 500 funded and non-funded clinical trials.

The Harvard-Thorndike Laboratory, the nation's oldest clinical research laboratory, has been located on this site since 1973. BIDMC also shares important clinical and research programs with institutions such as the Dana-Farber/Harvard Cancer Center, Joslin Diabetes Center, and Children's Hospital.

Who We Are

BIDMC is part of Beth Israel Lahey Health, a health care system that brings together academic medical centers and teaching hospitals, community and specialty hospitals, and more than 38,000 employees in a shared mission to expand access to great care and advance the science and practice of medicine through groundbreaking research and education.

Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center (HMFP) is one of the largest physician organizations in New England, dedicated to excellence and innovation in patient care, education, and research. As a physician-led organization, HMFP partners with more than 2,400 providers to support the delivery of exceptional care, promote professional development, and foster balance at work and home. HMFP physicians have faculty affiliations with Harvard Medical School (HMS) and provide care throughout the Beth Israel Lahey Health (BILH) system and additional hospitals across Massachusetts.

Pay Range:

$269,000 - $321,000

The base pay range reflects what Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center (HMFP) reasonably and in good faith expects to pay for this role at the time of posting and may be modified from time to time. Actual compensation within this range may be determined based on several factors, including academic appointment, work experience, specialty training, geography of work location, anticipated productivity, FTE basis, and role expectations. In addition to base compensation, this role may be eligible for performance-based incentives, which may include bonuses for productivity and quality HMFP also offers a comprehensive and generous employee benefits program to eligible employees, including health, dental, vision, life, and disability insurance, as well as retirement plan(s) with employer contributions.